Search News Archives
Follow us on
Conferences | Events

Media Partners


Exploring Personalized Treatments for Bladder Cancer with scRNA-seq

publication date: Sep 5, 2018
author/source: Dolomite

Associate Professor Iver Nordentoft

A Dolomite Bio system is helping researchers in the Department of Molecular Medicine at Aarhus University Hospital in Denmark to explore the potential of single cell RNA sequencing for personalized treatment of bladder cancer.

Associate Professor Iver Nordentoft explained: “Our focus is on translational research to obtain a deeper understanding of bladder cancer, identifying and validating molecular markers that could aid personalized medicine. In early stage bladder cancer, the main clinical challenge is to predict disease recurrence, aggressiveness and treatment response.”

“Previously, we used next generation sequencing (NGS, DNA- and RNA-Seq) for cancer genomics studies, but we are now moving into the single cell arena to delve further into tumor heterogeneity, clonality and the tumor microenvironment. NGS-based RNA analysis of bulk tumors identified three major molecular groups predicting different disease outcomes, and we are now using the scRNA-seq System to determine the specific cell type contribution of these molecular subgroups. In other words, are specific immune cells over- or under-represented in the aggressive tumors? Furthermore, characterization of cell type composition in apparently normal bladder tissue may also contribute to the development of molecular tools and clinically-applicable pipelines to predict the likely aggressiveness of the disease and the frequency of recurrence.”

“We had been considering single cell sequencing for this application for a while, having realized the potential of the Drop-Seq protocol described in the Macosko paper1. I attended a demonstration of Dolomite Bio’s scRNA-seq System, thought it was very promising and liked the company, and so we purchased a system for our laboratory. Our research team decided to choose a platform that was as open as possible to accommodate new developments and changing laboratory needs, and this was one of the main reasons for selecting the Dolomite Bio system. The open design helps to futureproof the system, giving us the option to run emerging protocols – such as high throughput sequencing of single nuclei by DroNc-Seq – in the future. I am very pleased with the system and the support I receive from Dolomite Bio,” Iver concluded.

more from this company

If you have not logged into the website then please enter your details below.


Popular this month


Thermo Fisher Scientific’s Analytical Instruments Receive Industry Recognition with Prestigious Awards

Bruker Introduces new SKYSCAN 1273 Benchtop 3D X-ray Microscope

How To Increase Productivity & Efficiency In Laboratories

Opportunities and challenges in the booming North American cannabis market

ZEISS Develops First Multifunctional Smart Glass

Eppendorf & Science Prize for Neurobiology 2019: Call for Entries!

Industry forecast for analytical instruments market in 2019

MGI Introduces Automated Sample Preparation Workstations, Streamlining Genomic Sequencing Workflow

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!

Know the Unknown – with Cora Raman Spectrometers from Anton Paar




Can't find what you are looking for?

Search by company or by product

Company Name:


Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd